Classification
Compound class	Antibody
Approved drug?	Yes (FDA (2004), EMA (2005))
WHO Essential Medicine	WHO Model List of Essential Medicines (21st List, 2019). Access PDF version.

International Nonproprietary Names
INN number	INN
8017	bevacizumab

Synonyms

Avastin® | rhuMAb-VEGF

Comments

Vascular endothelial growth factor A inhibitor. Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record. Biosimilars: Bevacizumab-awwb (Mvasi®, developed by Amgen) was the first bevacizumab biosimilar to be FDA approved (September 2017). Approval covers treatment of a range of cancers, including certain colorectal, lung, brain, kidney and cervical cancers. Pfizer's biosimilar (PF-06439535; bevacizumab-bvzr; trade name Zirabev®) received EMA and FDA marketing authorisations in 2019. It is indicated for specified colorectal, breast, renal, lung, and cervical cancers by the EMA, with approval for breast cancers replaced by approval for recurrent glioblastoma under the FDA authorisation. SB8 is in development by Samsung Bioepis (Phase 3 NCT02754882). CBT124 (Cipla BioTech; NCT02879097) is in Phase 3 development.

Database Links
Specialist databases
IMGT/mAb-DB	24
Other databases
GtoPdb PubChem SID	178103377
PubChem SID	178103377
Search PubMed clinical trials	bevacizumab
Search PubMed titles	bevacizumab
Search PubMed titles/abstracts	bevacizumab
Wikipedia	Bevacizumab